---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-053593"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T04:56:47.407835+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# VYNE Therapeutics licenses BD2-selective BET inhibitors, selects development candidate VYN202

## Summary
- $3.75M upfront payment for exclusive worldwide license; up to $68.75M in milestones plus tiered royalties.
- VYN202 is oral BD2-selective BET inhibitor for immuno-inflammatory conditions; IND-enabling studies ongoing.
- Preclinical data suggests VYN202 may be best-in-class with potent anti-inflammatory and anti-fibrotic effects.
- IND filing planned by year-end; VYNE expects to advance VYN202 into clinical development.
- VYNE also obtained rights to additional BD2-selective BET inhibitor compounds from Tay Therapeutics.

## SEC filing metadata
- accession: 0001104659-23-053593
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465923053593/0001104659-23-053593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465923053593/tm2314020d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-053593
- JSON: https://secwatch.observer/filing/0001104659-23-053593.json
- Plain text: https://secwatch.observer/filing/0001104659-23-053593.txt

## Key facts
- Material Agreements
  VYNE Therapeutics Inc. entered into License Agreement with Tay Therapeutics Limited (formerly known as In4Derm Limited, “Tay”) valued at up to an aggregate of $43.75 million (effective 2023-04-28).
  - Action: entry
  - Agreement: license
  - Counterparty: Tay Therapeutics Limited (formerly known as In4Derm Limited, “Tay”)
  - Value: up to an aggregate of $43.75 million
  - Effective: 2023-04-28
  source text: On April 28, 2023, VYNE Therapeutics Inc. (the “Company”) and Tay Therapeutics Limited (formerly known as In4Derm Limited, “Tay”) entered into a License Agreement (the “License Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465923053593/0001104659-23-053593-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.